FreshRecalls

⚠ Data freshness notice: the most recent refresh of NHTSA was incomplete, so a very recent recall may be missing. Everything shown is accurate as of the last checked time on this page — for anything time-critical, confirm with the official sources linked below.

FDAClass II · Drug · Recalled July 8, 2026

Levothyroxine Sodium Tablets recall — ACCORD HEALTHCARE, INC.

Hazard: Subpotent Drug

Class II: may cause temporary or medically reversible health consequences.

View the official FDA enforcement record (openFDA) ↗

Official recall ID
D-0656-2026
Brand
ACCORD HEALTHCARE
Classification
Class II
Units affected
6432 bottles
Recall status
Ongoing
Initiated
Voluntary: Firm initiated

Description

Levothyroxine Sodium Tablets, USP, 300 mcg (0.3mg), 90 Tablets bottles, Rx only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: lntas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, INDIA, NDC 16729-458-15.

Affected products

Companies & origin

Recalling firm location
Raleigh, NC, United States
Firm address
8041 Arco Corporate Dr Ste 200, N/A, 27617-2010

Identifying details (verbatim from the notice)

Product codes / lots
Lot # D2401522, Exp Date: 06/2026.
Distribution
US Nationwide.
Firm notified the public via
Letter
FDA event ID
99194
Recall initiated
June 8, 2026
FDA classified
June 30, 2026
FDA report date
July 8, 2026

Source: U.S. Food & Drug Administration. This page mirrors the official public-domain record verbatim; the linked government source is authoritative. Source last checked July 23, 2026 at 11:04 PM UTC.

Report a data error on this page